AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28256778 — intervention group
Group type: EXPERIMENTAL
Intervention: Rechargeable implantable pulse generators (rIPGs) implanted at the next IPG depletion after 2007 until 2012.
Number of subjects: 10
Study 27429413 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation intervention (6.5min video related to healthcare acquired infection and 4 simulated situations requiring hand hygiene)
Number of subjects: 131
Study 27429413 — intervention group
Group type: COMPARATOR
Intervention: Control group (received the same lecture pertaining to hand hygiene)
Number of subjects: 131
Study 27429413 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of hand hygiene technique using Glo Germ and UV photography
Number of subjects: 131
Study 21574837 — intervention group
Group type: EXPERIMENTAL
Intervention: GapSeal gel
Number of subjects: 45
Study 21574837 — intervention group
Group type: EXPERIMENTAL
Intervention: O‐ring
Number of subjects: 45
Study 21574837 — intervention group
Group type: COMPARATOR
Intervention: Unsealed group
Number of subjects: 45
Study 22374870 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone treatment
Number of subjects: 829
Study 22374870 — intervention group
Group type: COMPARATOR
Intervention: No prednisolone treatment (Control)
Number of subjects: 829
Study 22374870 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 829
Study 22374870 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunnybrook score at baseline
Number of subjects: 829
Study 22374870 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunnybrook score at days 11 to 17
Number of subjects: 829
Study 22374870 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunnybrook score at 1 month
Number of subjects: 829
Study 21250567 — intervention group
Group type: EXPERIMENTAL
Intervention: NaF/triclosan/copolymer dentifrice
Number of subjects: 0
Study 21250567 — intervention group
Group type: COMPARATOR
Intervention: MFP dentifrice
Number of subjects: 0
Study 21250567 — intervention group
Group type: COMPARATOR
Intervention: Non-fluoridated dentifrice
Number of subjects: 0
Study 18328136 — intervention group
Group type: EXPERIMENTAL
Intervention: Penehyclidine hydrochloride
Number of subjects: 45
Study 18328136 — intervention group
Group type: EXPERIMENTAL
Intervention: Anisodamine
Number of subjects: 45
Study 18328136 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 45
Study 16279817 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoral appliance (IOA) using superelastic coils
Number of subjects: 40
Study 16279817 — intervention group
Group type: COMPARATOR
Intervention: Extraoral appliance (EOA) (cervical headgear)
Number of subjects: 40
Study 11867979 — intervention group
Group type: EXPERIMENTAL
Intervention: Graphic method for gastric tube depth of insertion
Number of subjects: 88
Study 11867979 — intervention group
Group type: COMPARATOR
Intervention: NEX method for gastric tube depth of insertion
Number of subjects: 88
Study 11867979 — intervention group
Group type: EXPERIMENTAL
Intervention: Graphic method (absolute values)
Number of subjects: 88
Study 11867979 — intervention group
Group type: COMPARATOR
Intervention: NEX method (absolute values)
Number of subjects: 88
Study 10467970 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 96
Study 10467970 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 7825534 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet A (12% of total energy intake)
Number of subjects: 28
Study 7825534 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet B (21% of total energy intake)
Number of subjects: 28
Study 7825534 — intervention group
Group type: COMPARATOR
Intervention: Comparison of PT rates between men and women
Number of subjects: 28
Study 2354694 — intervention group
Group type: EXPERIMENTAL
Intervention: gari as eba 50 g
Number of subjects: 11
Study 2354694 — intervention group
Group type: EXPERIMENTAL
Intervention: lafun 50 g
Number of subjects: 11
Study 2354694 — intervention group
Group type: EXPERIMENTAL
Intervention: parboiled cassava flakes 76 g
Number of subjects: 11
Study 2354694 — intervention group
Group type: COMPARATOR
Intervention: 75 g glucose
Number of subjects: 11
Study 6254456 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetrahydrocannabinol (THC)
Number of subjects: 55
Study 6254456 — intervention group
Group type: COMPARATOR
Intervention: Prochlorperazine
Number of subjects: 55
Study 6254456 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 30339035 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet-Exercise trainings with creative drama method
Number of subjects: 76
Study 30339035 — intervention group
Group type: COMPARATOR
Intervention: Control Group (no intervention)
Number of subjects: 76
Study 29620558 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity (HI) strength training (n=16)
Number of subjects: 48
Study 29620558 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-Intensity (LI) strength training (n=16)
Number of subjects: 48
Study 29620558 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=16) with no specific exercise programme
Number of subjects: 48
Study 28974267 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component exercise programme and nutritional supplementation
Number of subjects: 51
Study 28974267 — intervention group
Group type: COMPARATOR
Intervention: Usual care control
Number of subjects: 51
Study 26665746 — intervention group
Group type: EXPERIMENTAL
Intervention: Art Therapy (AT) in addition to Psychotherapy (PT)
Number of subjects: 141
Study 26665746 — intervention group
Group type: COMPARATOR
Intervention: Psychotherapy (PT) alone
Number of subjects: 141
Study 23980737 — intervention group
Group type: EXPERIMENTAL
Intervention: CET (Concurrent Exercise Training)
Number of subjects: 47
Study 23980737 — intervention group
Group type: EXPERIMENTAL
Intervention: RET (Resistance Exercise Training)
Number of subjects: 47
Study 23980737 — intervention group
Group type: EXPERIMENTAL
Intervention: EET (Endurance Exercise Training)
Number of subjects: 47
Study 23980737 — intervention group
Group type: EXPERIMENTAL
Intervention: All training interventions
Number of subjects: 47
Study 21802150 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (OLZ)
Number of subjects: 160
Study 21802150 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (RIS)
Number of subjects: 160
Study 21802150 — intervention group
Group type: COMPARATOR
Intervention: Control group (no concomitant mood stabilizers)
Number of subjects: 160
Study 19109574 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine (2.0 mg/kg/day)
Number of subjects: 126
Study 19109574 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (0.3 mg/kg/week, increased to 25 mg/week)
Number of subjects: 126
Study 17146324 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 17146324 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.5 mg.kg caffeine
Number of subjects: 6
Study 17146324 — intervention group
Group type: EXPERIMENTAL
Intervention: 9.0 mg.kg caffeine
Number of subjects: 6
Study 12710402 — intervention group
Group type: EXPERIMENTAL
Intervention: VaxGen vaccine
Number of subjects: 0
Study 10671332 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole (100 mg orally twice daily)
Number of subjects: 210
Study 10671332 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study 9085974 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprotinin
Number of subjects: 97
Study 9085974 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study 7693932 — intervention group
Group type: EXPERIMENTAL
Intervention: Peroperative cholangiography (PC)
Number of subjects: 285
Study 7693932 — intervention group
Group type: COMPARATOR
Intervention: No peroperative cholangiography (Control group)
Number of subjects: 285
Study 3964534 — intervention group
Group type: EXPERIMENTAL
Intervention: Neat oil suspension (Sandimmun)
Number of subjects: 12
Study 3964534 — intervention group
Group type: COMPARATOR
Intervention: Milk as dispersant
Number of subjects: 12
Study 3964534 — intervention group
Group type: COMPARATOR
Intervention: Milk + chocolate flavouring as dispersant
Number of subjects: 12
Study 3964534 — intervention group
Group type: COMPARATOR
Intervention: Orange juice as dispersant
Number of subjects: 12
Study 29602814 — intervention group
Group type: EXPERIMENTAL
Intervention: Limited respiratory monitoring (LRM)
Number of subjects: 14
Study 29602814 — intervention group
Group type: COMPARATOR
Intervention: Polysomnography (PSG)
Number of subjects: 14
Study 29936921 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid ubiquinol (100 mg/d)
Number of subjects: 50
Study 29936921 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 27083776 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention Arm A (invitation letter)
Number of subjects: 5265
Study 27083776 — intervention group
Group type: COMPARATOR
Intervention: Control Arm C (no invitation)
Number of subjects: 5265
Study 27083776 — intervention group
Group type: EXPERIMENTAL
Intervention: Excluding women who participated in screening annually
Number of subjects: 5265
Study 26569364 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating levels of miR‐199a‐3p, miR‐423‐3p, and miR‐let‐7i‐5p
Number of subjects: 98
Study 26569364 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in creatinine
Number of subjects: 98
Study 26569364 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase in NGAL
Number of subjects: 98
Study 26569364 — intervention group
Group type: EXPERIMENTAL
Intervention: MiR‐199a‐3p
Number of subjects: 98
Study 22721373 — intervention group
Group type: EXPERIMENTAL
Intervention: Training condition (participants exposed to the Target Object)
Number of subjects: 0
Study 22721373 — intervention group
Group type: COMPARATOR
Intervention: Control condition (participants not exposed to the Target Object)
Number of subjects: 0
Study 20393402 — intervention group
Group type: EXPERIMENTAL
Intervention: 35 mg risedronate weekly, vitamin D, and calcium
Number of subjects: 101
Study 20393402 — intervention group
Group type: COMPARATOR
Intervention: Control group (vitamin D and calcium only)
Number of subjects: 101
Study 18706096 — intervention group
Group type: EXPERIMENTAL
Intervention: ROLL
Number of subjects: 120
Study 18706096 — intervention group
Group type: COMPARATOR
Intervention: WL
Number of subjects: 120
Study 15917045 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Eating and Lifestyle Program (10 weekly weight loss classes)
Number of subjects: 237
Study 15917045 — intervention group
Group type: EXPERIMENTAL
Intervention: Further group counseling or staff-facilitated self-help (Phase 2)
Number of subjects: 237
Study 15917045 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (baseline to final visit; average 18 months total duration)
Number of subjects: 237
Study 15917045 — intervention group
Group type: COMPARATOR
Intervention: Control group (follow-up clinic visits only)
Number of subjects: 237
Study 15917045 — intervention group
Group type: EXPERIMENTAL
Intervention: Completers of the program
Number of subjects: 237
Study 12526935 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg/day for 14 days
Number of subjects: 52
Study 12526935 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg/day for 14 days
Number of subjects: 52
Study 12526935 — intervention group
Group type: EXPERIMENTAL
Intervention: PPI treatment
Number of subjects: 52
Study 12526935 — intervention group
Group type: EXPERIMENTAL
Intervention: BreathID
Number of subjects: 52
Study 12526935 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear regression analysis
Number of subjects: 52
Study 10685198 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed pushing protocol
Number of subjects: 0
Study 10685198 — intervention group
Group type: COMPARATOR
Intervention: Control group (directed pushing at full cervical dilation)
Number of subjects: 0
Study 8595542 — intervention group
Group type: EXPERIMENTAL
Intervention: Acrivastine + pseudoephedrine
Number of subjects: 702
Study 8595542 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudoephedrine
Number of subjects: 702
Study 8595542 — intervention group
Group type: EXPERIMENTAL
Intervention: Acrivastine
Number of subjects: 702
Study 8595542 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 702
Study 3190996 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble aspirin 600 mg
Number of subjects: 140
Study 3190996 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble aspirin 900 mg
Number of subjects: 140
Study 3190996 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble aspirin 1200 mg
Number of subjects: 140
Study 3190996 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin tablet 1200 mg
Number of subjects: 140
Study 3190996 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin tablets 600 mg
Number of subjects: 140
Study 3190996 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin tablets 900 mg
Number of subjects: 140
Study 3190996 — intervention group
Group type: EXPERIMENTAL
Intervention: Soluble aspirin
Number of subjects: 140
Study 3190996 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 1136678 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscular exercise programme
Number of subjects: 27
Study 1136678 — intervention group
Group type: COMPARATOR
Intervention: Control group (no muscular exercise)
Number of subjects: 27
Study 31891553 — intervention group
Group type: EXPERIMENTAL
Intervention: Interportal capsulotomy with closure (CC)
Number of subjects: 150
Study 31891553 — intervention group
Group type: EXPERIMENTAL
Intervention: Interportal capsulotomy without closure (IC)
Number of subjects: 150
Study 31891553 — intervention group
Group type: COMPARATOR
Intervention: T-capsulotomy without closure (TC)
Number of subjects: 150
Study 31045534 — intervention group
Group type: EXPERIMENTAL
Intervention: Support Vector Machine (SVM) with Particle Swarm Optimization (PSO)
Number of subjects: 0
Study 31045534 — intervention group
Group type: EXPERIMENTAL
Intervention: Support Vector Machine (SVM) with Genetic Algorithm (GA)
Number of subjects: 0
Study 31045534 — intervention group
Group type: COMPARATOR
Intervention: Support Vector Machine (SVM) without optimization
Number of subjects: 0
Study 26552099 — intervention group
Group type: EXPERIMENTAL
Intervention: AllergiSense smartphone app and sensing system for injection training and feedback
Number of subjects: 0
Study 26552099 — intervention group
Group type: COMPARATOR
Intervention: Paper-only control group
Number of subjects: 0
Study 25409596 — intervention group
Group type: EXPERIMENTAL
Intervention: Pexacerfont (300 mg/day for 7 days, followed by 100 mg/day for 23 days)
Number of subjects: 54
Study 25409596 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label pexacerfont (same dosing regimen)
Number of subjects: 54
Study 25409596 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study 21205590 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent implantation (SES)
Number of subjects: 91
Study 21205590 — intervention group
Group type: COMPARATOR
Intervention: 90Sr/90Y-VBT (Control)
Number of subjects: 91
Study 18456379 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive skill learning in PD patients
Number of subjects: 10
Study 18456379 — intervention group
Group type: COMPARATOR
Intervention: Cognitive skill learning in healthy controls
Number of subjects: 10
Study 21485105 — intervention group
Group type: EXPERIMENTAL
Intervention: hANP (0.025 microg x kg(‐1) x min(‐1))
Number of subjects: 39
Study 21485105 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 39
Study 17849195 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-presented automatization exercises
Number of subjects: 14
Study 17849195 — intervention group
Group type: COMPARATOR
Intervention: Computer-presented exercises aimed at the use of context for word identification and comprehension
Number of subjects: 14
Study 12127830 — intervention group
Group type: EXPERIMENTAL
Intervention: Appropriate care with hylan G‐F 20 (AC+H)
Number of subjects: 255
Study 12127830 — intervention group
Group type: COMPARATOR
Intervention: Appropriate care without hylan G‐F 20 (AC)
Number of subjects: 255
Study 9445108 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic laser ablation (mean 4 sessions, energy 4709 joules)
Number of subjects: 17
Study 9445108 — intervention group
Group type: COMPARATOR
Intervention: Control group (no laser ablation, only antireflux surgery)
Number of subjects: 17
Study 7988780 — intervention group
Group type: EXPERIMENTAL
Intervention: Glipizide treatment
Number of subjects: 0
Study 2738213 — intervention group
Group type: EXPERIMENTAL
Intervention: Social problem-solving therapy
Number of subjects: 39
Study 2738213 — intervention group
Group type: EXPERIMENTAL
Intervention: Training in the problem-orientation component
Number of subjects: 39
Study 791320 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbitone (50 mg) 8-hourly for 3 weeks
Number of subjects: 17
Study 791320 — intervention group
Group type: EXPERIMENTAL
Intervention: Orphenadrine (100 mg) 8-hourly for 3 weeks
Number of subjects: 17
Study 791320 — intervention group
Group type: COMPARATOR
Intervention: Chlorpromazine (100 mg) 8-hourly
Number of subjects: 17
Study 29228144 — intervention group
Group type: EXPERIMENTAL
Intervention: individualized texting for adherence building (iTAB)
Number of subjects: 398
Study 29228144 — intervention group
Group type: COMPARATOR
Intervention: standard care (SoC)
Number of subjects: 398
Study 27261084 — intervention group
Group type: EXPERIMENTAL
Intervention: Zip surgical skin closure device
Number of subjects: 214
Study 27261084 — intervention group
Group type: COMPARATOR
Intervention: Subcuticular sutures
Number of subjects: 214
Study 25151341 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized RA risk education based on demographics, RA-associated behaviors, genetics, and biomarkers
Number of subjects: 0
Study 25151341 — intervention group
Group type: COMPARATOR
Intervention: Standard RA information
Number of subjects: 0
Study 22476643 — intervention group
Group type: EXPERIMENTAL
Intervention: Heterozygosity at the D8S1179 locus
Number of subjects: 131
Study 22476643 — intervention group
Group type: COMPARATOR
Intervention: Control group (people over 90 years without CI)
Number of subjects: 131
Study 20410233 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasireotide 200-600 microg s.c. twice daily for 28 days
Number of subjects: 60
Study 20410233 — intervention group
Group type: COMPARATOR
Intervention: Octreotide 100 microg s.c. three times daily for 28 days
Number of subjects: 60
Study 18765397 — intervention group
Group type: EXPERIMENTAL
Intervention: Darapladib (160 mg daily)
Number of subjects: 330
Study 18765397 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 330
Study 16059596 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromazepam 3 mg
Number of subjects: 39
Study 16059596 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromazepam 6 mg
Number of subjects: 39
Study 16059596 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 12501878 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefditoren 200 mg BID
Number of subjects: 851
Study 12501878 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefditoren 400 mg BID
Number of subjects: 851
Study 12501878 — intervention group
Group type: COMPARATOR
Intervention: Cefpodoxime 200 mg BID
Number of subjects: 851
Study 10069786 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with OSA during hypoxia
Number of subjects: 28
Study 10069786 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with OSA during hypoxia with apnea
Number of subjects: 28
Study 8524980 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (CLO) 1.5 micrograms/kg
Number of subjects: 0
Study 8524980 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (CLO) 2.5 micrograms/kg
Number of subjects: 0
Study 8524980 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (DZP) 5 mg
Number of subjects: 0
Study 8524980 — intervention group
Group type: EXPERIMENTAL
Intervention: Diazepam (DZP) 10 mg
Number of subjects: 0
Study 2261347 — intervention group
Group type: EXPERIMENTAL
Intervention: IFN plus melphalan plus prednisone (IFN-MP)
Number of subjects: 50
Study 2261347 — intervention group
Group type: COMPARATOR
Intervention: melphalan plus prednisone (MP)
Number of subjects: 50
Study 35214 — intervention group
Group type: EXPERIMENTAL
Intervention: Clobazam 20 mg
Number of subjects: 8
Study 35214 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol + Clobazam 20 mg
Number of subjects: 8
Study 35214 — intervention group
Group type: COMPARATOR
Intervention: Alcohol alone
Number of subjects: 8
Study 35214 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 35214 — intervention group
Group type: COMPARATOR
Intervention: Clobazam alone
Number of subjects: 8
Study 35214 — intervention group
Group type: COMPARATOR
Intervention: Alcohol + Placebo
Number of subjects: 8
Study 30821640 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal value orientation: self-enhancement value
Number of subjects: 0
Study 30821640 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal value orientation: self-transcendence value
Number of subjects: 0
Study 30821640 — intervention group
Group type: EXPERIMENTAL
Intervention: Value-invoking message: invoked
Number of subjects: 0
Study 30821640 — intervention group
Group type: EXPERIMENTAL
Intervention: Value-invoking message: non-invoked
Number of subjects: 0
Study 30821640 — intervention group
Group type: EXPERIMENTAL
Intervention: Freedom threat: high
Number of subjects: 0
Study 30821640 — intervention group
Group type: EXPERIMENTAL
Intervention: Freedom threat: low
Number of subjects: 0
Study 28240597 — intervention group
Group type: COMPARATOR
Intervention: PR (pegylated interferon + ribavirin) for 24-48 weeks
Number of subjects: 34
Study 28240597 — intervention group
Group type: EXPERIMENTAL
Intervention: TVR (telaprevir) + PR for 12-24 weeks
Number of subjects: 34
Study 28240597 — intervention group
Group type: EXPERIMENTAL
Intervention: TVR + PR
Number of subjects: 34
Study 25733676 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypnotic medication as an add-on treatment to a selective serotonin reuptake inhibitor
Number of subjects: 40
Study 25733676 — intervention group
Group type: COMPARATOR
Intervention: Placebo as an add-on treatment to a selective serotonin reuptake inhibitor
Number of subjects: 40
Study 22897785 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral immunotherapy (OIT) with cow's milk protein increased from 0.06 mg to a maximum of 6400 mg over 23 weeks.
Number of subjects: 28